Aberdeen Group
XENE icon

Aberdeen Group’s Xenon Pharmaceuticals XENE Stock Holding History

Aberdeen Group’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.7M Sell
408,736
-201,193
-33% -$11.2M 0.03% 393
2026
Q1 		$35.5M Sell
609,929
-140,362
-19% -$6.47M 0.06% 282
2025
Q4 		$33.6M Buy
750,291
+171,146
+30% +$7.19M 0.05% 293
2025
Q3 		$23.3M Buy
579,145
+57,653
+11% +$2.03M 0.04% 380
2025
Q2 		$16.3M Buy
521,492
+117,338
+29% +$3.83M 0.03% 471
2025
Q1 		$13.6M Buy
404,154
+120,255
+42% +$4.57M 0.03% 491
2024
Q4 		$11.1M Buy
283,899
+35,588
+14% +$1.47M 0.02% 491
2024
Q3 		$9.78M Buy
248,311
+35,809
+17% +$1.44M 0.02% 526
2024
Q2 		$8.29M Buy
212,502
+180,466
+563% +$7.21M 0.02% 542
2024
Q1 		$1.38M Hold
32,036
– – ﹤0.01% 805
2023
Q4 		$1.48M Buy
+32,036
New +$1.13M ﹤0.01% 800

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Aberdeen Group's XENE Position: Q2 2026 in Review

Aberdeen Group reduced its Xenon Pharmaceuticals (XENE) stake by 33% in Q2 2026, selling an estimated $11.2M and leaving 408,736 shares worth $24.7M. The position accounts for 0.03% of the portfolio, ranked #393.

Aberdeen Group first reported a position in XENE in Q4 2023 and has held it in 11 quarters since. The position peaked at $35.5M in Q1 2026. 316 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Aberdeen Group held 408,736 shares of Xenon Pharmaceuticals worth $24.7M as of Q2 2026.
  • Aberdeen Group sold 201,193 Xenon Pharmaceuticals shares in Q2 2026, an estimated $11.2M.
  • Xenon Pharmaceuticals made up 0.03% of Aberdeen Group's portfolio in Q2 2026, its #393 holding.
  • Aberdeen Group first reported a position in Xenon Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • Aberdeen Group's Xenon Pharmaceuticals position peaked at $35.5M in Q1 2026.
  • 316 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.